Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers. - Phadke S; Miller KD; Shah A; Danciu OC; Chen Y; Yu M; Burkard ME; Wisinski KB (Breast cancer research and treatment, 2025)